76.06
price up icon0.03%   0.00
 
loading
Merck Co Inc stock is traded at $76.06, with a volume of 2.40M. It is up +0.03% in the last 24 hours and down -2.46% over the past month. Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$76.06
Open:
$75.96
24h Volume:
2.40M
Relative Volume:
0.15
Market Cap:
$190.96B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
11.07
EPS:
6.87
Net Cash Flow:
$17.04B
1W Performance:
-5.41%
1M Performance:
-2.46%
6M Performance:
-21.19%
1Y Performance:
-42.01%
1-Day Range:
Value
$75.69
$76.74
1-Week Range:
Value
$73.31
$78.55
52-Week Range:
Value
$73.31
$134.63

Merck Co Inc Stock (MRK) Company Profile

Name
Name
Merck Co Inc
Name
Phone
908-740-4000
Name
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
Employee
75,000
Name
Twitter
@Merck
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
MRK's Discussions on Twitter

Compare MRK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
MRK
Merck Co Inc
76.05 201.96B 63.92B 17.43B 17.04B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
749.38 678.30B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
151.89 370.87B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
183.62 335.74B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
109.75 215.19B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
65.92 300.99B 43.59B 15.04B 10.74B 3.3766

Merck Co Inc Stock (MRK) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Feb-18-25 Downgrade Deutsche Bank Buy → Hold
Feb-10-25 Downgrade TD Cowen Buy → Hold
Jan-08-25 Downgrade Truist Buy → Hold
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-10-24 Resumed BofA Securities Buy
Dec-04-24 Upgrade HSBC Securities Hold → Buy
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-11-24 Downgrade Daiwa Securities Buy → Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Mar-11-24 Downgrade Societe Generale Hold → Sell
Jan-04-24 Upgrade TD Cowen Market Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Buy
Oct-27-23 Upgrade BMO Capital Markets Market Perform → Outperform
Oct-20-23 Upgrade UBS Neutral → Buy
Jul-14-23 Initiated HSBC Securities Hold
Apr-13-23 Upgrade Citigroup Neutral → Buy
Mar-28-23 Downgrade Societe Generale Buy → Hold
Mar-13-23 Downgrade Wells Fargo Overweight → Equal Weight
Mar-06-23 Initiated Jefferies Buy
Feb-22-23 Upgrade Wolfe Research Peer Perform → Outperform
Jan-04-23 Upgrade BofA Securities Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
Oct-10-22 Upgrade Guggenheim Neutral → Buy
Sep-14-22 Upgrade Berenberg Hold → Buy
Jul-06-22 Upgrade Daiwa Securities Neutral → Buy
Jun-06-22 Resumed SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Dec-17-21 Initiated Goldman Buy
Dec-16-21 Initiated Daiwa Securities Neutral
Dec-13-21 Downgrade UBS Buy → Neutral
Dec-09-21 Initiated Wells Fargo Overweight
Dec-07-21 Downgrade Guggenheim Buy → Neutral
Nov-29-21 Downgrade Citigroup Buy → Neutral
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-01-21 Upgrade Argus Hold → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-27-21 Resumed Truist Buy
May-20-21 Downgrade Argus Buy → Hold
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Aug-03-20 Upgrade Goldman Neutral → Buy
Jun-12-20 Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Oct-17-19 Resumed BofA/Merrill Neutral
Aug-16-19 Initiated SVB Leerink Outperform
Jul-03-19 Initiated Mizuho Buy
May-28-19 Initiated Goldman Neutral
May-13-19 Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18 Reiterated Citigroup Buy
Oct-09-18 Resumed Guggenheim Buy
Apr-23-18 Upgrade Goldman Neutral → Buy
Apr-17-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18 Upgrade Barclays Equal Weight → Overweight
Mar-12-18 Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18 Reiterated Leerink Partners Mkt Perform
Feb-07-18 Reiterated Morgan Stanley Equal-Weight
Jan-16-18 Upgrade SunTrust Hold → Buy
View All

Merck Co Inc Stock (MRK) Latest News

pulisher
09:12 AM

Merck: Phase 3 trial begins in esophageal cancer - marketscreener.com

09:12 AM
pulisher
07:00 AM

Breakthrough Cancer Drug Enters Phase 3 Trial: Merck Targets Deadly Esophageal Cancer with 15% Survival Rate - Stock Titan

07:00 AM
pulisher
May 16, 2025

Merck: progress report in hypertension (PAH) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Merck to Present New Clinical and Outcomes Research Data at The - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Business Wire

May 16, 2025
pulisher
May 16, 2025

MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer - Clinical Trials Arena

May 16, 2025
pulisher
May 16, 2025

[Pfizer Inc, AstraZeneca, Merck & Co. Inc] Breakthroughs In Bladder Cancer Treatment Market Research 2025 - openPR.com

May 16, 2025
pulisher
May 16, 2025

Merck & Co., Inc. (NYSE:MRK) Earns “Neutral” Rating from Citigroup - Defense World

May 16, 2025
pulisher
May 16, 2025

Traders Buy Large Volume of Put Options on Merck & Co., Inc. (NYSE:MRK) - Defense World

May 16, 2025
pulisher
May 16, 2025

Merck Continues to Deliver Growth in Turbulent Times - chemeurope.com

May 16, 2025
pulisher
May 15, 2025

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers - insights.citeline.com

May 15, 2025
pulisher
May 15, 2025

Decoding Merck & Co's Options Activity: What's the Big Picture? - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With KeytrudaMerck & Co (NYSE:MRK) - Benzinga

May 15, 2025
pulisher
May 15, 2025

Why Merck & Co., Inc. (MRK) Is Among the Best Cheap Stocks to Buy Now for Beginners - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.

May 15, 2025
pulisher
May 15, 2025

Merck & Co., Inc. (MRK): One of the Best Dividend Growth Stocks with High Yields - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Jefferies not seeing significant impact to Merck, Bristol from draft guidance - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Merck brings another big business to small town De Soto - NewsBreak: Local News & Alerts

May 15, 2025
pulisher
May 15, 2025

Merck's (MRK) Keytruda Hits Milestone in Ovarian Cancer Trial - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer - MSN

May 15, 2025
pulisher
May 15, 2025

Merck (MRK) Achieves Key Milestones in Ovarian Cancer Trial with KEYTRUDA | MRK Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Merck stock rises as Keytruda succeeds in ovarian cancer (MRK) - Seeking Alpha

May 15, 2025
pulisher
May 15, 2025

Merck’s Keytruda shows promise in ovarian cancer trial - Investing.com

May 15, 2025
pulisher
May 15, 2025

The Zacks Analyst Blog Highlights Oracle, IBM, Merck and Earth Science Tech - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Merck secures FDA approval for Welireg to treat rare tumours - World Pharmaceutical Frontiers

May 15, 2025
pulisher
May 14, 2025

13 Best Cheap Stocks to Invest in for Beginners - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Top Analyst Reports for Oracle, IBM & Merck - MSN

May 14, 2025
pulisher
May 14, 2025

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL) - BioSpace

May 14, 2025
pulisher
May 14, 2025

Merck (MRK) Gains FDA Approval for Welireg in Treating Rare Tumo - GuruFocus

May 14, 2025
pulisher
May 14, 2025

US FDA expands use of Merck's cancer drug for adrenal gland tumors - Reuters

May 14, 2025
pulisher
May 14, 2025

Merck Gets FDA Approval for Welireg to Treat Rare Tumors - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

FDA Approves Merck'S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL) - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Transcript : Merck & Co., Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

FDA Approves Merck's (MRK) Welireg for Rare Tumor Treatment - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Merck wins FDA label expansion for Welireg (MRK:NYSE) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

FDA Approves Merck's (MRK) Welireg for PPGL Treatment | MRK Stoc - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Assessing Merck & Co: Insights From 4 Financial Analysts - Benzinga

May 14, 2025
pulisher
May 14, 2025

Germany's Merck drops China surcharge on orders after US-China tariff deal - NewsBreak: Local News & Alerts

May 14, 2025
pulisher
May 14, 2025

Merck & Co (MRK) Faces Downgrade and Price Target Reduction by C - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Citi cuts Merck stock rating to neutral, slashes target to $84 - Investing.com

May 14, 2025
pulisher
May 14, 2025

Citi cuts Merck stock rating to neutral, slashes target to $84 By Investing.com - Investing.com India

May 14, 2025
pulisher
May 14, 2025

Analyst recommendations: AbbVie, KKR, Merck, Toast, Uber… - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Merck (MRK) Sees Downgrade as Growth Challenges Loom | MRK Stock News - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Merck Animal Health Investing $895M in US Manufacturing and R&D Facilities - Powder & Bulk Solids

May 13, 2025
pulisher
May 13, 2025

Is Merck & Co. (MRK) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Merck, JNJ, Bristol , and Other Big Pharma Stocks Counted on a Price Negotiation Loophole. It May Be Closing. - Barron's

May 13, 2025
pulisher
May 13, 2025

Merck & Co. (MRK) Shows Bullish Option Activity as Volatility Ri - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Merck invests $895M in Kansas manufacturing and research facilities - Feedstuffs

May 13, 2025
pulisher
May 13, 2025

The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen - Zacks Investment Research

May 13, 2025

Merck Co Inc Stock (MRK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general NVO
$65.62
price up icon 1.98%
drug_manufacturers_general GSK
$37.63
price up icon 0.15%
drug_manufacturers_general NVS
$109.63
price up icon 0.08%
$272.88
price down icon 0.04%
drug_manufacturers_general PFE
$22.87
price up icon 0.17%
Cap:     |  Volume (24h):